DDInter122 DDInter53
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Alpelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Alpelisib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Alpelisib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Alpelisib may lead to a major life threatening interaction when taken with Edoxaban